Effects of Lixisenatide Versus Liraglutide (Short- and Long-Acting GLP-1 Receptor Agonists) on Esophageal and Gastric Function in Patients With Type 2 Diabetes.

Quast DR, Schenker N, Menge BA, Nauck MA, Kapitza C, Meier JJ

Diabetes care9 Jul 2020Cited by 47 (Europe PMC)

PMID32647054DOI10.2337/dc20-0720PepBankPUB-32647054

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study10

9 results from studies that gave the peptide. 9 results from people.

01HumanRandomized controlled trialEfficacy outcome
In adults with type 2 diabetes, liraglutide had a less pronounced influence on gastric emptying after breakfast than lixisenatide.
In plain wordsIn adults with type 2 diabetes, liraglutide slowed stomach emptying less than lixisenatide.
Peptide
Liraglutide
Outcome
DecreaseGastric emptying after breakfast, liraglutide versus lixisenatide
Study
n = 57
Comparator
Lixisenatide
Outcome group
Gastrointestinal motility · Gastrointestinal
Studied dose
Dose not stated · 10 weeksAs given in this study (human).
Source sentences
Summary
Lixisenatide exerted a more pronounced influence on gastric emptying after breakfast than liraglutide.
1 context sentence(design, population, supporting numbers)
Summary · context
A total of 57 subjects with type 2 diabetes were randomized to a 10-week treatment with lixisenatide or liraglutide.
Report a problemFND-3264705402
02HumanRandomized controlled trialSafety outcome
In adults with type 2 diabetes, the number of esophageal reflux episodes did not differ between lixisenatide and liraglutide.
In plain wordsIn adults with type 2 diabetes, the number of acid reflux episodes was not different between lixisenatide and liraglutide.
Peptide
Liraglutide
Outcome
No significant changeNumber of reflux episodes in the lower esophagus, lixisenatide versus liraglutide
Study
n = 57
Comparator
Lixisenatide
Outcome group
Gastrointestinal adverse events · Gastrointestinal
Studied dose
Dose not stated · 10 weeksAs given in this study (human).
Measurements
Reflux episodes
33.7 episodes
lixisenatide
Reflux episodes
40.1 episodes
liraglutide
Source sentences
Summary
There was no difference in the number of reflux episodes (mean ± SEM 33.7 ± 4.1 vs. 40.1 ± 5.3 for lixisenatide and liraglutide, respectively, P = 0.17)
1 context sentence(design, population, supporting numbers)
Summary · context
A total of 57 subjects with type 2 diabetes were randomized to a 10-week treatment with lixisenatide or liraglutide.
Report a problemFND-3264705403
03HumanRandomized controlled trialSafety outcome
In adults with type 2 diabetes, the DeMeester score of gastroesophageal reflux did not differ between lixisenatide and liraglutide.
In plain wordsIn adults with type 2 diabetes, the measured extent of acid reflux was not different between lixisenatide and liraglutide.
Peptide
Liraglutide
Outcome
No significant changeExtent of gastroesophageal reflux (DeMeester score), lixisenatide versus liraglutide
Study
n = 57
Comparator
Lixisenatide
Outcome group
Gastrointestinal adverse events · Gastrointestinal
Studied dose
Dose not stated · 10 weeksAs given in this study (human).
Measurements
DeMeester score
35.1
lixisenatide
DeMeester score
39.7
liraglutide
Source sentences
Summary
or the extent of gastroesophageal reflux (DeMeester score) (35.1 ± 6.7 vs. 39.7 ± 7.5, P = 0.61)
1 context sentence(design, population, supporting numbers)
Summary · context
A total of 57 subjects with type 2 diabetes were randomized to a 10-week treatment with lixisenatide or liraglutide.
Report a problemFND-3264705404
04HumanRandomized controlled trialSafety outcome
In adults with type 2 diabetes, neither liraglutide nor lixisenatide produced significant changes from baseline in other esophageal motility parameters or lower esophageal sphincter function.
In plain wordsIn adults with type 2 diabetes, liraglutide did not significantly change esophageal movement or the valve at the stomach entrance compared with before treatment.
Peptide
Liraglutide
Outcome
No significant changeEsophageal motility and lower esophageal sphincter function
Study
n = 57
Outcome group
Gastrointestinal adverse events · Gastrointestinal
Studied dose
Dose not stated · 10 weeksAs given in this study (human).
Source sentences
Summary
No significant changes from baseline in other parameters of esophageal motility and lower esophageal sphincter function were observed.
2 context sentences(design, population, supporting numbers)
Summary · context
Neither lixisenatide nor liraglutide had significant effects on esophageal reflux or motility.
Summary · context
A total of 57 subjects with type 2 diabetes were randomized to a 10-week treatment with lixisenatide or liraglutide.
Report a problemFND-3264705405
05HumanRandomized controlled trialSafety outcome
In adults with type 2 diabetes, reflux episodes averaged 33.7 ± 4.1 with lixisenatide versus 40.1 ± 5.3 with liraglutide (P = 0.17).
In plain wordsIn adults with diabetes, reflux episodes were numerically fewer with lixisenatide than liraglutide, without a significant difference.
Peptide
Lixisenatide
Outcome
DecreaseReflux episodes
Study
n = 57
Comparator
Liraglutide
Outcome group
Gastrointestinal function · Gastrointestinal
Studied dose
Dose not stated · 10 weeksAs given in this study (human).
Measurements
Reflux episodes (mean)
33.7 episodes
lixisenatide
Reflux episodes (mean)
40.1 episodes
liraglutide
Source sentences
Summary
There was no difference in the number of reflux episodes (mean ± SEM 33.7 ± 4.1 vs. 40.1 ± 5.3 for lixisenatide and liraglutide, respectively, P = 0.17)
1 context sentence(design, population, supporting numbers)
Summary · context
A total of 57 subjects with type 2 diabetes were randomized to a 10-week treatment with lixisenatide or liraglutide.
Report a problemFND-3264705408
06HumanRandomized controlled trialSafety outcome
In adults with type 2 diabetes, DeMeester scores averaged 35.1 ± 6.7 with lixisenatide versus 39.7 ± 7.5 with liraglutide (P = 0.61).
In plain wordsIn adults with diabetes, reflux scores were numerically lower with lixisenatide than liraglutide, without a significant difference.
Peptide
Lixisenatide
Outcome
DecreaseDeMeester score
Study
n = 57
Comparator
Liraglutide
Outcome group
Gastrointestinal function · Gastrointestinal
Studied dose
Dose not stated · 10 weeksAs given in this study (human).
Measurements
DeMeester score (mean)
35.1 score
lixisenatide
DeMeester score (mean)
39.7 score
liraglutide
Source sentences
Summary
or the extent of gastroesophageal reflux (DeMeester score) (35.1 ± 6.7 vs. 39.7 ± 7.5, P = 0.61)
1 context sentence(design, population, supporting numbers)
Summary · context
A total of 57 subjects with type 2 diabetes were randomized to a 10-week treatment with lixisenatide or liraglutide.
Report a problemFND-3264705409
07HumanRandomized controlled trialEfficacy outcome
In adults with type 2 diabetes, liraglutide delayed gastric emptying half-time by 25 min from baseline over 10 weeks.
In plain wordsIn adults with type 2 diabetes, liraglutide slowed the emptying of the stomach by 25 minutes compared with before treatment.
Peptide
Liraglutide
Outcome
IncreaseGastric emptying half-time change from baseline
Study
n: not reported in source
Outcome group
Gastrointestinal motility · Gastrointestinal
Studied dose
Dose not stated · 10 weeksAs given in this study (human).
Measurements
Gastric emptying half-time change
25 min
liraglutide
Source sentences
Summary
and by 25 min (3, 46) with liraglutide (P = 0.025).
1 context sentence(design, population, supporting numbers)
Summary · context
A total of 57 subjects with type 2 diabetes were randomized to a 10-week treatment with lixisenatide or liraglutide.
Report a problemFND-3264705401
08HumanNon-randomized trialActivity measurement
In adults with type 2 diabetes, lixisenatide delayed gastric emptying half-time by 52 min (95% CI 16, 88; P = 0.0065).
In plain wordsIn adults with diabetes, gastric emptying took longer during lixisenatide treatment than at baseline.
Peptide
Lixisenatide
Outcome
IncreaseGastric emptying half-time
Study
n: not reported in source
Comparator
Baseline
Outcome group
Gastrointestinal function · Gastrointestinal
Studied dose
Dose not stated · 10 weeksAs given in this study (human).
Measurements
Half-time change
52 min
lixisenatide
95% CI lower
16 min
change
95% CI upper
88 min
change
Source sentences
Summary
Gastric emptying half-time was delayed by 52 min (Δ 95% CI 16, 88) with lixisenatide (P = 0.0065) and by 25 min (3, 46) with liraglutide (P = 0.025).
1 context sentence(design, population, supporting numbers)
Summary · context
A total of 57 subjects with type 2 diabetes were randomized to a 10-week treatment with lixisenatide or liraglutide.
Report a problemFND-3264705407
09HumanNon-randomized trialSafety outcome
In adults with type 2 diabetes, other esophageal motility and lower esophageal sphincter parameters showed no significant change from baseline, and neither lixisenatide nor liraglutide had significant effects on esophageal motility.
In plain wordsIn adults with diabetes, other measures of esophageal movement and sphincter function did not change significantly from baseline during lixisenatide or liraglutide treatment.
Peptide
Lixisenatide
Outcome
No significant changeOther esophageal motility and lower esophageal sphincter function parameters
Study
n: not reported in source
Comparator
Baseline
Outcome group
Gastrointestinal function · Gastrointestinal
Studied dose
Dose not stated · 10 weeksAs given in this study (human).
Source sentences
Summary
No significant changes from baseline in other parameters of esophageal motility and lower esophageal sphincter function were observed.
2 context sentences(design, population, supporting numbers)
Summary · context
Neither lixisenatide nor liraglutide had significant effects on esophageal reflux or motility.
Summary · context
A total of 57 subjects with type 2 diabetes were randomized to a 10-week treatment with lixisenatide or liraglutide.
Report a problemFND-3264705410

Studies that did not test the peptide alone1

In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Liraglutide.

10HumanNot a test of Liraglutide aloneRandomized controlled trialEfficacy outcome
In adults with type 2 diabetes, pooled lixisenatide and liraglutide decreased gastric acidity by 20.7% from baseline.
In plain wordsIn adults with type 2 diabetes, the two GLP-1 drugs lixisenatide and liraglutide taken together lowered stomach acidity compared with before treatment.
Peptide
Liraglutide
Outcome
DecreaseGastric acidity change with pooled short- and long-acting GLP-1 receptor agonists
Study
n = 57
Outcome group
Gastrointestinal motility · Gastrointestinal
Measurements
Gastric acidity change
−20.7%
pooled lixisenatide and liraglutide
Source sentences
Summary
Gastric acidity decreased significantly by -20.7% (-40.6, -0.8) (P = 0.042) with the GLP-1 RAs.
1 context sentence(design, population, supporting numbers)
Summary · context
A total of 57 subjects with type 2 diabetes were randomized to a 10-week treatment with lixisenatide or liraglutide.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-3264705406

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 stopped early · source ClinicalTrials.gov (opens in a new tab)

TerminatedPhase 1NCT02231658

Effects of Victoza® Versus Lyxumia® on Gastroesophageal Reflux, Gastric Emptying and Gastric Acid Secretion

Profil Institut für Stoffwechselforschung GmbHn = 10916 Jul 2015 to 23 Jul 2018

Diabetes Mellitus

Trial page ClinicalTrials.govUpdated 17 Oct 2018

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Versions 4 to 5Current
28 Oct 2026, 02:03 UTC
The same notice was added 2 times, first on 28 Oct 2026, 02:03 UTC. The status did not change between them.
Study results updated
Version 3
27 Oct 2026, 16:36 UTC
Study data updated · source update from Europe PMC
Version 2
12 Oct 2026, 11:11 UTC
Study results updated
Version 1
9 Oct 2026, 03:05 UTC
First added · source update from Europe PMC